Lead Product(s) : DR10624
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Doer Biologics Doses First Patient in DR10624 Phase 2 Liver Disease Study
Details : DR10624 is a first-in-class long-acting tri-agonist targeting FGF21R, GLP-1R, and glucagon receptor. It is being evaluated for the treatment of liver fibrosis associated with MASLD.
Product Name : DR10624
Product Type : Protein
Upfront Cash : Inapplicable
April 23, 2025
Lead Product(s) : DR10624
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chiglitazar Sodium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Results from Phase II Trial (CGZ203 Study) of Chiglitazar Monotherapy for NASH
Details : Bilessglu (chiglitazar sodium) is a novel peroxisome proliferator activation-related receptor pan-agonist, which is being evaluated for the treatment of non-alcoholic steatohepatitis.
Product Name : Bilessglu
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Chiglitazar Sodium
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis Announces Strategic Decisions on FXR Agonist ASC42
Details : ASC42 is an orally available FXR agonist, small molecule drug candidate, which is currently being evaluated for the treatment of primary biliary cholangitis.
Product Name : ASC42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2024
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LIVMARLI® (maralixibat) oral solution is a minimally absorbed ileal bile acid transporter (IBAT) inhibitor and has also completed enrollment across the other global locations where the trial is open.
Product Name : Livmarli
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2023
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC41
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned
Details : ASC41 is a liver-targeted prodrug, and its active metabolite is a selective THRβ agonist. Ascletis announced positive clinical results in overweight and obese subjects for ASC41.
Product Name : ASC41
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : ASC41
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China
Details : CAN108 (maralixibat) oral solution is an orally administered, once-daily,IBAT inhibitor approved by USFDA for treatment of cholestatic pruritus in patients with Alagille syndrome (one year of age and older.
Product Name : Livmarli
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC41
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASC41 is a liver-targeted prodrug, and its active metabolite is a selective THRβ agonist. THRβ is highly expressed in the liver, and THRβ agonists have demonstrated to be active in reducing low density lipoprotein (LDL), triglyceride (TG) and hepatic ...
Product Name : ASC41
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : ASC41
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : US Food & Drug Administration
Deal Size : Undisclosed
Deal Type : Agreement
Details : The company had a productive discussion with FDA as part of an End-of-Phase 2 meeting, regarding the key elements of the study design of HTD1801 in patients with PSC and will be submitting a Phase 3 protocol to FDA for review and comment.
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 22, 2022
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : US Food & Drug Administration
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : US Food & Drug Administration
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company had a productive discussion with FDA as part of an End-of-Phase 2 meeting, regarding the key elements of the study design of HTD1801 in patients with PSC and will be submitting a Phase 3 protocol to FDA for review and comment.
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2022
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : US Food & Drug Administration
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
Details : An orally active ionic salt of berberine and ursodeoxycholic acid in development for chronic liver diseases, HTD1801 is currently being evaluated in Phase 2 trials in PSC, NASH and PBC.
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2021
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable